Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Riikka-Leena Leskelä, Sonja Korhonen, Ira Haavisto, Mikko Nuutinen, Emmi Peltonen, Fredrik Herse, Sari Käkelä, Anna-Maija Autere, Katja Nolvi, Satu Tiainen, Maria Silvoniemi, Eeva-Liisa Junnila, Jarkko Ahvonen, Aija Knuuttila & Jussi Koivunen. (2023) Trends in cost of treatment of lung cancer patients in 2014–2019 in Finland – a descriptive register study. Acta Oncologica 62:6, pages 587-593.
Read now
Read now
Amanda M. Kong, Melissa Pavilack, Hairong Huo, Rahul Shenolikar, Meghan Moynihan, Elizabeth H. Marchlewicz, Christina Chebili-Larson, Stella Min & Deepa S. Subramaniam. (2021) Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US . Journal of Medical Economics 24:1, pages 328-338.
Read now
Read now
Beilei Cai, Zheng-Yi Zhou, Weiguang Xue, Nisha C. Hazra, Mukesh Singh, Dinesh Mishra, Diana Brixner, Gary Oderda & Joseph Biskupiak. (2021) Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States. Journal of Medical Economics 24:1, pages 131-139.
Read now
Read now
Katharina Verleger, John R Penrod, Melinda Manley Daumont, Caitlyn Solem, Linlin Luo, Cynthia Macahilig & Nadine Hertel. (2020) Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe. ClinicoEconomics and Outcomes Research 12, pages 23-33.
Read now
Read now
Nimer S. Alkhatib, Kenneth Ramos, Brian Erstad, Marion Slack, Ali McBride, Sandipan Bhattacharjee & Ivo Abraham. (2020) Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing. Journal of Medical Economics 23:11, pages 1215-1222.
Read now
Read now
Carl Samuelsen, Jonathan Lim, Amanda Golembesky, Sulena Shrestha, Li Wang & Ingolf Griebsch. (2020) Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States. Journal of Medical Economics 23:1, pages 48-53.
Read now
Read now
Articles from other publishers (22)
Wen You, Asal Pilehvari, Ruoding Shi, Wendy Cohn, Christina Sheffield, Philip I‐Fon Chow, Becca Anne Krukowski & Roger Anderson. (2023)
A
multi‐dimensional
assessment of financial hardship of cancer patients using existing health system data
. Cancer Medicine.
Crossref
Crossref
Rossybelle Amorrortu, Melany Garcia, Yayi Zhao, Issam El Naqa, Yoganand Balagurunathan, Dung-Tsa Chen, Thanh Thieu, Matthew B Schabath & Dana E Rollison. (2023) Overview of approaches to estimate real-world disease progression in lung cancer. JNCI Cancer Spectrum 7:6.
Crossref
Crossref
Julie Vanderpoel, Bruno Emond, Isabelle Ghelerter, Katherine Milbers, Marie-Hélène Lafeuille, Patrick Lefebvre & Lorie A. Ellis. (2023) Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis. PharmacoEconomics - Open 7:4, pages 617-626.
Crossref
Crossref
Cliff Molife, Katherine B. Winfree, Hollie Bailey, Yulia D’yachkova, Cameron Forshaw, Sangmi Kim, Kaisa-Leena Taipale & Tarun Puri. (2023) Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study. Advances in Therapy 40:7, pages 3135-3168.
Crossref
Crossref
Meng-Jung Wen, Han-Lin Hsu, Chia-Lun Chang, Jou-Han Wang, Chun-Nan Kuo, Yen-Chun Hsin & Elizabeth H. Chang. (2023) Understanding the medication experience of patients with advanced non-small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: A phenomenological study. PLOS ONE 18:5, pages e0286333.
Crossref
Crossref
Di Wu, Jianxiang Xie, Huizhen Dai & Wentong Fang. (2022) Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation. BMC Health Services Research 22:1.
Crossref
Crossref
Mary Boulanger, Carley Mitchell, Jeffrey Zhong & Melinda Hsu. (2022) Financial toxicity in lung cancer. Frontiers in Oncology 12.
Crossref
Crossref
Xinke Zhang, Richard W DeClue, Lisa Herms, Mo Yang, Vivek Pawar, Elizabeth T Masters, Mary Ruisi, Kevin Chin & Vamsidhar Velcheti. (2021) Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer. Immunotherapy 13:18, pages 1521-1533.
Crossref
Crossref
Soo-Dam Kim, Jae-Ho Yang, Eun-Bin Kwag, Ji-Hye Park, So-Jung Park & Hwa-Seung Yoo. (2021) Nonclinical Safety Pharmacology Study of the Herbal Product HAD-B1. Evidence-Based Complementary and Alternative Medicine 2021, pages 1-10.
Crossref
Crossref
Cristina Merkhofer, Shasank Chennupati, Qin Sun, Keith D. Eaton, Renato G. Martins, Scott D. Ramsey & Bernardo H. L. Goulart. (2021) Effect of Clinical Trial Participation on Costs to Payers in Metastatic Non–Small-Cell Lung Cancer. JCO Oncology Practice 17:8, pages e1225-e1234.
Crossref
Crossref
Zhuohong Li, Juncai Tian, Lei Du, Ying Gao, Yao Wang, Fengming You & Li Wang. (2021) Anlotinib exerts anti‐cancer efficiency on lung cancer stem cells in vitro and in vivo through reducing NF‐κB activity. Journal of Cellular and Molecular Medicine 25:12, pages 5547-5559.
Crossref
Crossref
So-Jung Park, Soo-Dam Kim, Eun-Bin Kwag, Ji Hye Park & Hwa-Seung Yoo. (2021) Acute and Subchronic Toxicological Evaluation of the Herbal Product HAD-B1 in Rats. Evidence-Based Complementary and Alternative Medicine 2021, pages 1-13.
Crossref
Crossref
Garrett Crothers, Nisha B Shah, Moonjung Kim & Autumn D Zuckerman. (2020) Development of a quality measures tool for the utilization of tyrosine kinase inhibitors in non-small cell lung cancer: An integrated specialty pharmacy initiative. Journal of Oncology Pharmacy Practice 26:6, pages 1441-1451.
Crossref
Crossref
Robert Wood & Gavin Taylor-Stokes. (2019) Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage. BMC Cancer 19:1.
Crossref
Crossref
Yi Liao, Xianming Fan & Xue Wang. (2019) Effects of different metastasis patterns, surgery and other factors on the prognosis of patients with stage�IV non‑small cell lung cancer: A Surveillance, Epidemiology, and End Results (SEER) linked database analysis. Oncology Letters.
Crossref
Crossref
Durovski Darko, Randazzo Ornella, J. Peters Godefridus & Giovannetti Elisa. (2019) The role of developmental signaling pathways in non-small cell lung carcinoma. Journal of Molecular and Clinical Medicine 2:2, pages 41.
Crossref
Crossref
Zhonghan Zhang, Kangmei Zeng, Shen Zhao, Yuanyuan Zhao, Xue Hou, Fan Luo, Feiteng Lu, Yaxiong Zhang, Ting Zhou, Yuxiang Ma, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang & Hongyun Zhao. (2019) Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis. Therapeutic Advances in Medical Oncology 11, pages 175883591989165.
Crossref
Crossref
Xiaohua Gu, Qiang Zhang, Yun-Bo Chu, Yi-Yang Zhao, Yan-Jun Zhang, David Kuo, Betty Su & Bin Wu. (2019) Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Lung Cancer 127, pages 84-89.
Crossref
Crossref
Jun Zhu, Wei He, Ming Ye, Jie Fu, Yun-Bo Chu, Yi-Yang Zhao, Yan-Jun Zhang, David Kuo & Bin Wu. (2018) Cost–effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung. Future Oncology 14:27, pages 2833-2840.
Crossref
Crossref
Yuki Tomonaga, Kevin ten Haaf, Thomas Frauenfelder, Malcolm Kohler, Roger D. Kouyos, Mohaned Shilaih, Matthias Lorez, Harry J. de Koning, Matthias Schwenkglenks & Milo A. Puhan. (2018) Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking—A modelling study. Lung Cancer 121, pages 61-69.
Crossref
Crossref
Ernestina Menasalvas Ruiz, Juan Manuel Tuñas, Guzmán Bermejo, Consuelo Gonzalo Martín, Alejandro Rodríguez-González, Massimiliano Zanin, Cristina González de Pedro, Marta Méndez, Olga Zaretskaia, Jesús Rey, Consuelo Parejo, Juan Luis Cruz Bermudez & Mariano Provencio. (2018) Profiling Lung Cancer Patients Using Electronic Health Records. Journal of Medical Systems 42:7.
Crossref
Crossref
Tom MunyerBridgette Kanz Schroader. 2017. PharmacotherapyFirst: A Multimedia Learning Resource. PharmacotherapyFirst: A Multimedia Learning Resource.